Literature DB >> 9473153

Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE) in human immunodeficiency virus type-1 seropositive subjects.

R B Moss1, W Giermakowska, P Lanza, J L Turner, M R Wallace, F C Jensen, G Theofan, S P Richieri, D J Carlo.   

Abstract

Lymphocyte proliferation responses to gp120-depleted HZ321 virus (clade A) antigen were compared to BAL human immunodeficiency virus (HIV) virus antigen (clade B) responses, clade E HIV virus antigen responses, and purified native p24 antigen responses in 15 human immunodeficiency virus type-1 (HIV-1) seropositive subjects immunized with a whole-killed inactivated gp120-depleted HIV-1 antigen in Incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE). A significant increase in lymphocyte proliferation to HZ321 antigen was observed after immunization with the HIV-1 immunogen (p = 0.02). A strong association was demonstrated between the HIV-1 immunizing antigen, HZ321, and native p24 antigen responses (r = 0.80, p < 0.0001). Furthermore, a strong association in terms of proliferative responses was demonstrated between HZ321 virus (clade A) responses and BAL virus (clade B) (r = 0.95, p < 0.0001) and clade E virus antigen (r = 0.92, p < 0.0001). Proliferative responses to HIV antigens also correlated with baseline CD4 counts. Taken together, these results support the specificity of immune responses induced by REMUNE (HIV-1 immunogen). The development of cross-reactive immune responses between clades and to the more conserved epitopes of the virus have implications in the development of therapeutic and prophylactic HIV vaccines.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9473153     DOI: 10.1089/vim.1997.10.221

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  8 in total

1.  Cross-reactive T-helper responses in patients infected with different subtypes of human immunodeficiency virus type 1.

Authors:  A C Leandersson; G Gilljam; M Fredriksson; J Hinkula; A Alaeus; K Lidman; J Albert; G Bratt; E Sandström; B Wahren
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

2.  Effects of adjuvants for human use in systemic lupus erythematosus (SLE)-prone (New Zealand black/New Zealand white) F1 mice.

Authors:  E Favoino; E I Favia; L Digiglio; V Racanelli; Y Shoenfeld; F Perosa
Journal:  Clin Exp Immunol       Date:  2014-01       Impact factor: 4.330

3.  In vitro p24 antigen-stimulated lymphocyte proliferation and beta-chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (Remune).

Authors:  R B Moss; M R Wallace; P Lanza; W Giermakowska; F C Jensen; G Theofan; C Chamberlin; S P Richieri; D J Carlo
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

4.  A double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic, HIV-1-infected thai subjects with CD4-cell counts of >300.

Authors:  V Churdboonchart; C Sakondhavat; S Kulpradist; B I Na Ayudthya; V Chandeying; S Rugpao; C Boonshuyar; W Sukeepaisarncharoen; W Sirawaraporn; D J Carlo; R Moss
Journal:  Clin Diagn Lab Immunol       Date:  2000-09

5.  T-helper-cell proliferative responses to whole-killed human immunodeficiency virus type 1 (HIV-1) and p24 antigens of different clades in HIV-1-infected subjects vaccinated with HIV-1 immunogen (Remune).

Authors:  R B Moss; W Giermakowska; M R Wallace; J Savary; F Jensen; D J Carlo
Journal:  Clin Diagn Lab Immunol       Date:  2000-09

6.  Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus.

Authors:  Elena Chertova; Julian W Bess; Bruce J Crise; Raymond C Sowder II; Terra M Schaden; Joanne M Hilburn; James A Hoxie; Raoul E Benveniste; Jeffrey D Lifson; Louis E Henderson; Larry O Arthur
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

Review 7.  Application of radiation technology in vaccines development.

Authors:  Ho Seong Seo
Journal:  Clin Exp Vaccine Res       Date:  2015-07-29

Review 8.  Viral inactivation by light.

Authors:  Mohammad Sadraeian; Le Zhang; Farzaneh Aavani; Esmaeil Biazar; Dayong Jin
Journal:  eLight       Date:  2022-09-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.